Weight loss drugs have become quite popular in the past years. However, there are a few aspects of the drug that need to be explored more. One such aspect is its effect on postmenopausal women.

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

I am a 75-year-old woman who isn’t prediabetic or diabetic. My BMI is 31.2. My doctor has prescribed a trial of metformin for ...

Ongoing research is needed to fully understand their risks, especially for long-term and higher-dose users. However, many ...

Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

Ozempic has gained a lot of popularity with many referring to it as the miracle weight loss drug However how much do you ...

US-based consumer insights company 1Q has launched a prescription-verified panel of users of GLP-1 drugs, including weight ...

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

Around 1.5 million people in the UK are thought to be using weight loss jabs, with many paying privately as NHS supplies ...

The Delhi High Court has directed the Central Drugs Standard Control Organisation (CDSCO) and the Drug Controller General of ...